Met Life Investment Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 53,020 shares of CRNX stock, worth $1.94 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
53,020
Previous 44,935
17.99%
Holding current value
$1.94 Million
Previous $2.3 Million
18.08%
% of portfolio
0.02%
Previous 0.01%
Shares
41 transactions
Others Institutions Holding CRNX
# of Institutions
252Shares Held
89.2MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$333 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$254 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$228 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$225 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$198 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.97B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...